3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Motor Activity
15
Neoplasms
11
Breast Neoplasms
11
Prostatic Neoplasms
7
Obesity
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
4
Signs and Symptoms
3
Sarcopenia
3
Polycystic Ovary Syndrome
3
Lung Neoplasms
3
Diabetes Mellitus, Type 2
3
Uterine Cervical Neoplasms
2
Pharyngeal Neoplasms
2
Osteoporosis, Postmenopausal
2
Osteoporosis
2
Lymphoma
2
Leukemia
2
Laryngeal Neoplasms
2
Fatigue
2
Diabetes Mellitus
2
Weight Loss
1
Uterine Neoplasms
1
Urinary Incontinence
1
Stroke
1
Squamous Cell Carcinoma of Head and Neck
1
Sedentary Behavior
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Interventions
Rituximab
47
Cyclophosphamide
26
fludarabine
13
ibrutinib
12
Doxorubicin
11
Vincristine
10
Etoposide
10
Cytarabine
10
Prednisone
9
Bortezomib
9
pembrolizumab
7
fludarabine phosphate
6
Lenalidomide
6
Inotuzumab Ozogamicin
6
obinutuzumab
5
Mycophenolic Acid
5
Melphalan
5
Carmustine
5
tositumomab I-131
4
ibritumomab tiuxetan
4
Tacrolimus
4
Prednisolone
4
Methotrexate
4
Gemcitabine
4
Bendamustine Hydrochloride
4
Antilymphocyte Serum
4
tocilizumab
3
tazemetostat
3
Whole-Body Irradiation
3
Vorinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoma, B-Cell
×
Resistance Training
×
Clear all
NCT05556239
2025-12-08
STAY-STRONG
Rigshospitalet, Denmark
Phase NA
Completed
42 enrolled